Scinai

19/03/2026

𝐒𝐭𝐫𝐨𝐧𝐠 𝐦𝐨𝐦𝐞𝐧𝐭𝐮𝐦 𝐟𝐨𝐫 Scinai 𝐚𝐬 𝐭𝐡𝐞 𝐭𝐞𝐚𝐦 𝐡𝐞𝐚𝐝𝐬 𝐭𝐨 𝐁𝐈𝐎-𝐄𝐮𝐫𝐨𝐩𝐞 𝐒𝐩𝐫𝐢𝐧𝐠 𝟐𝟎𝟐𝟔🇵🇹
At this year’s event, Scinai is showcasing strong progress across two key growth engines:

𝐂𝐃𝐌𝐎: 𝐈𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐞𝐝 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐭𝐨 𝐂𝐨𝐦𝐦𝐞𝐫𝐜𝐢𝐚𝐥 𝐒𝐮𝐩𝐩𝐥𝐲
Fresh off the acquisition of Recipharm Israel and a strategic collaboration with Recipharm, Scinai steps onto the international stage with expanded CDMO capabilities
🔹 cGMP biologics development & manufacturing in Jerusalem
🔹 cGMP small molecule API capabilities in Yavne
🔹 Expanded global capacity and flexibility via Recipharm
➡️ A seamless path from early development to commercialization—designed to reduce risk and accelerate timelines for biotech and pharma partners.

𝐏𝐈𝐏𝐄𝐋𝐈𝐍𝐄: 𝐀𝐝𝐯𝐚𝐧𝐜𝐢𝐧𝐠 𝐈𝐦𝐦𝐮𝐧𝐨𝐥𝐨𝐠𝐲 & 𝐈𝐧𝐟𝐥𝐚𝐦𝐦𝐚𝐭𝐢𝐨𝐧 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧
In parallel, Scinai continues to advance its pipeline of antibody-based immunotherapies:
🔹 Targeting autoimmune and inflammatory diseases
🔹 Strong focus on dermatology
🔹 Built on assets licensed from leading research institutions
➡️ A growing portfolio with promising scientific and clinical potential.

If you’re attending, make sure to visit the Scinai team at Booth #24 to explore collaboration opportunities across both CDMO services and pipeline innovation.

Read the full press release: https://lnkd.in/euUzbrCr

02/03/2026

Today we announced the ex*****on of an updated amendment to the binding option agreement for the of PinCell S.r.l., and the submission of a revised application under the European Funds for the Modern Economy (FENG) SMART Path program.

The Company's revised application seeks €12 million in non-dilutive, non-repayable funding to support a €15 million integrated R&D program for PC111 a fully human monoclonal antibody targeting soluble Fas Ligand (sFasL) for the treatment of pemphigus vulgaris (PV) and Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN), representing 80% project co-financing.

The Company expects a funding decision within approximately three to four months following submission.

Read more: https://www.prnewswire.com/news-releases/scinai-signs-second-amendment-to-pincell-option-agreement-and-submits-revised-12-million-non-dilutive-feng-application-to-advance-pc111-through-human-proof-of-concept-302701108.html

24/02/2026

In Case You Missed It - A Major Step Forward for Scinai!

Last week, we announced a transformative agreement with Recipharm - and it marks an exciting new chapter for Scinai.

The transaction brings together infrastructure, capital support, and a commercial partnership designed to accelerate our CDMO strategy while strengthening our financial foundation.

In a challenging biotech environment, this deal:
✔️ Adds immediate operational capabilities
✔️ Provides meaningful runway
✔️ Aligns us with a global CDMO leader
✔️ Creates a platform for scalable growth

In the video below, Amir shares why this transaction is such a powerful move for Scinai right now - and what it unlocks for the future.

Don’t miss it.

19/02/2026

𝐖𝐞𝐥𝐜𝐨𝐦𝐢𝐧𝐠 𝐭𝐡𝐞 𝐑𝐞𝐜𝐢𝐩𝐡𝐚𝐫𝐦 𝐈𝐬𝐫𝐚𝐞𝐥 𝐓𝐞𝐚𝐦 𝐭𝐨 𝐭𝐡𝐞 𝐒𝐜𝐢𝐧𝐚𝐢 𝐅𝐚𝐦𝐢𝐥𝐲
Today, our leadership visited Recipharm Israel to personally welcome the new team members into the Scinai family.
We spoke about the integration process between our two companies and the exciting opportunities it brings, as well as the challenges that naturally arise along the way.
We walked away from the meeting energized, aligned, and more focused than ever on our shared mission. With a united vision and a motivated team, the path ahead is full of promise.
A big welcome to the team - looking forward to building our future together.

17/02/2026

: We have officially announced the completion of our of Recipharm Israel Ltd. and strategic commercial collaboration with Recipharm. This milestone marks a tremendously important step forward for Scinai’s manufacturing footprint, capabilities, and commercial positioning, strengthening our CDMO platform and creating a differentiated, end-to-end development and manufacturing offering spanning early development directly by Scinai and late-stage clinical and commercial supply by Recipharm.

Read more: https://www.scinai.com/press-releases/scinai-announces-completion-of-acquisition-of-recipharm-israel-ltd-and-strategic-commercial-collaboration-with-recipharm

05/02/2026

We believe that fostering curiosity starts with real-world exposure. This week, we were excited to host high school students for Apprentice Day at Scinai, where they toured our production facility, attended our business review meetings, and heard insights from our CEO, Amir Reichman, on thoughtful decision-making. Through these experiences, they saw how science, technology, and teamwork drive our daily work.

This visit reflects our commitment to strengthening community ties and encouraging the next generation to explore, question, and lead. We’re grateful for the chance to inspire young minds and to share the passion that drives our mission forward.

שמחנו לארח השבוע תלמידי תיכון מבית ספר ליד האוניברסיטה בירושלים, כחלק מהפעילות שלנו לחיזוק קשרי קהילה וקידום מדעני העתיד.

30/01/2026

Highlighting the below piece by our CEO, Amir Reichman, where he offers his perspective and insights on the VHH antibody space and that while these antibodies are not a "new technology", what matters more than ever in the current environment is the differentiation, clinical context, and ex*****on discipline required within development.

It is clear there is a renewed interest in this modality, and we at Scinai are excited to be at the forefront of innovation!

Bloomberg recently highlighted how large pharmaceutical companies such as Sanofi, AstraZeneca, and Eli Lilly are increasingly investing in nanobody-based biologics in an article titled “Llamas Are Big Pharma’s Secret Weapon to Find New Drugs” by Lisa Pham (January 23, 2026). The article descri...

17/12/2025

ICYMI: Scinai reported our Q3 earnings report last week!

📈 Revenue more than doubled year-over-year, driven by continued growth in our CDMO business and early traction in the U.S. market.
🏭 Non-dilutive funding secured to expand our fill-and-finish manufacturing capabilities, with commercial operations expected in 2026.
🧬 Disciplined R&D ex*****on, with focus on advancing our differentiated NanoAbs pipeline and pursuing significant EU STEP grant opportunities.
💼 Strengthened balance sheet, reflecting careful capital stewardship as we position the company for upcoming milestones.

As we head into 2026, Scinai is focused on scaling its CDMO platform, advancing pipeline programs toward key inflection points, and creating long-term shareholder value!

🔗 Link to the full earnings release in the comments section!

04/12/2025

Scinai CEO, Amir Reichman , is proud to represent Scinai Immunotherapeutics this week as part of the Rhineland-Palatinate Biotech Delegation in Germany!

The delegation is meeting leading institutions - including the Biotechnology Campus Mainz, BioVation RLP, biomindz – Life Science Hub Mainz, UniMed Mainz, Midas Pharma , and Boehringer Ingelheim - to deepen collaboration between Israel and one of Europe’s most vibrant life-science regions.

Amir is highlighting Scinai’s work developing novel I&I biologics and expanding our boutique CDMO capabilities, while connecting with partners across the German innovation ecosystem.

This is a great opportunity to strengthen ties, explore new partnerships, and showcase the impact of Scinai’s science and services!

02/12/2025

Scinai Q3 Earnings — Momentum Building Continues

We are pleased to share the latest results from Scinai: our CDMO business is gaining real traction, and we’ve made meaningful progress on strengthening our financial footing and I&I pipeline!

Key highlights:

📈 CDMO revenue growth continues to outpace expectations, reflecting increasing demand for our biologics manufacturing and development services.

💡 We’re executing on our dual–engine strategy: scaling CDMO services while advancing our proprietary R&D pipeline of nanoAbs for inflammation & immunology (I&I).

👇 On the balance-sheet and cash-flow side: we significantly improved liquidity, reduced net loss compared to prior period, and further de-risked operations via strategic funding.

✅ Taken together — these results underscore that Scinai is no longer just a biotech in waiting. We are executing on a sustainable, dual-track model that combines external-facing manufacturing services with internally developed therapeutics.

Thank you to all colleagues, partners, and investors for the continued trust. We look forward to what’s ahead in the next phase of growth!

(Link to PR in the comments)

16/11/2025

🚀 𝐖𝐞’𝐫𝐞 𝐥𝐢𝐯𝐞! 𝐒𝐜𝐢𝐧𝐚𝐢’𝐬 𝐮𝐩𝐠𝐫𝐚𝐝𝐞𝐝 𝐰𝐞𝐛𝐬𝐢𝐭𝐞 𝐢𝐬 𝐨𝐟𝐟𝐢𝐜𝐢𝐚𝐥𝐥𝐲 𝐥𝐚𝐮𝐧𝐜𝐡𝐞𝐝.

At Scinai, we aim to elevate drug development every step of the way, and we invite you to be part of our journey.

Take a deep dive into our exciting I&I pipeline, explore Scinai CDMO BioServices, and gain a glimpse into our 1,850 sqm cGMP facility and state-of-the-art labs. Discover client stories, information resources, and expert insights.

Our upgraded site brings it all together to give biotech innovators a clearer, smarter path forward.

👉 Explore the upgraded website: www.scinai.com

10/11/2025

Industry Insight: Why “Good Data” Sometimes Isn’t Good Enough

Recent Phase 3 readouts in the inflammation and immunology (I&I) space have shown that even statistically positive results may not be enough. Investors and prescribers are increasingly demanding meaningful differentiation: new therapies must not only work but deliver real-world value for patients, physicians, and payers.

At Scinai Immunotherapeutics, we’re addressing this challenge with a first-in-class intradermal nanobody platform designed to deliver biologics locally, directly to the site of inflammation, rather than systemically throughout the body.

Our lead psoriasis program targets patients underserved by current options, including:

Mild-to-moderate patients who wish to avoid chronic topical corticosteroid use due to side effects such as skin atrophy.
Patients using advanced topicals (e.g., ZorivE™, Vtama®) who struggle with daily application and adherence.
Phototherapy patients who must attend frequent outpatient sessions for weeks at a time.
Patients with lesions in sensitive areas (face, scalp, ge****ls, palms, soles) who may currently receive systemic biologics due to the psychosocial burden of their disease, even though their overall disease severity is limited.

Our intradermal administration is performed using a mesogun, a device already well established in dermatology for applications such as hair restoration and skin rejuvenation. This approach enables precise, virtually painless delivery of nanobody-based biologics directly into the affected skin.

By providing a localized, safer, and more convenient alternative to systemic biologics, our technology addresses a key unmet need: offering biologic-level efficacy appropriate to the patient’s disease severity while reducing systemic exposure, improving adherence, and lowering overall treatment costs.

As the field seeks innovation that goes beyond incremental efficacy improvements, Scinai’s localized nanobody platform offers a de-risked, differentiated path to redefining care for inflammatory skin diseases.

👉 Learn more at www.scinai.com